No Data
Teyi Pharmaceutical Group (002728.SZ): By the end of 2024, the inventory of cough relief tablets in the terminal channel has been largely consumed.
On January 14, Gelonghui reported that Teyi Pharmaceutical Group (002728.SZ) mentioned in a recent investor relations activity that after the relaxation of control policies in 2023, there has been a significant increase in the inventory of four types of medicines—cough relief, antipyretic, antibiotics, and anti-infection—among agents, pharmacies, and consumers compared to the previous year. In 2024, as the company organizes its sales channels for cough relief tablets, by the end of 2024, the inventory of cough relief tablets in terminal channels has been largely digested, laying a solid foundation for the future sales management of cough relief tablets across different specifications and channels.
Optimism Around Teyi Pharmaceutical GroupLtd (SZSE:002728) Delivering New Earnings Growth May Be Shrinking as Stock Declines 16% This Past Week
Teyi Pharmaceutical Group (002728.SZ) has once again passed the recognition as a high-tech enterprise.
Gelonghui, January 10th | Teyi Pharmaceutical Group (002728.SZ) announced that, according to the notice issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the State Administration of Taxation Guangdong Provincial Taxation Bureau regarding the publication of the first batch of high-tech enterprises in Guangdong for 2024, Teyi Pharmaceutical Group Co., Ltd. has once again passed the certification for high-tech enterprises, certificate number: GR202444001815, valid for 3 years.
Teyi pharmaceutical group (002728.SZ): The capacity of the modern traditional chinese medicine product line expansion and technological upgrade project is planned to be gradually released starting next year.
Gelonghui reported on December 4 that teyi pharmaceutical group (002728.SZ) stated on the investor interaction platform that the modernization of the traditional chinese medicine product line expansion and technology upgrade project has completed the renovation of the Chinese pill production workshop, the comprehensive formulation workshop and testing building have been constructed, with some already in use and others undergoing the installation of related equipment. Production capacity is planned to be gradually released starting next year.
Teyi Pharmaceutical Group (002728.SZ): Plans to change part of the use of raised funds.
Gelonghui December 2nd | Teyi Pharmaceutical Group (002728.SZ) announced that according to the company's 2023 simple procedure refinancing to raise funds for investment project progress, and combined with the current market environment, the company's own development global strategy and future development plan, in order to improve the efficiency of fund raising and investment return, after careful research and analysis, the company plans to change some of the uses of the funds raised, the unused balance of the raised funds for the 'Modern traditional chinese medicine decoction piece construction project' of RMB 210.3566 million to be changed to implement the company's 2021 non-public offering investment project 'modern traditional chinese medicine product line expansion'.
Teyi Pharmaceutical Group (002728.SZ): The company currently has no AI pharmaceutical business.
gelonhui November 20th | teyi pharmaceutical group (002728.SZ) stated on the investor interaction platform that the company currently has no business in AI pharmaceuticals.
Improved Earnings Required Before Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Stock's 29% Jump Looks Justified
